“We synthesized them and encapsulated them into a nano-vaccine that is needle-free and administered as a nasal spray,” Satchi-Fainaro said. The nano-vaccine proved effective against all major ...

Scientists at Stanford are developing a painless, topical vaccine using a common skin bacterium to trigger immunity.

Hope is on the horizon for needle-phobic patients as Griffith University researchers have created a new influenza vaccine composition designed to be administered via the nose. Griffith University ...

Vaxxas’ proprietary high-density microarray patch (HD-MAP) technology is currently being evaluated in a phase 1 clinical study of the first needle-free COVID-19 vaccine, having demonstrated ...

Vaxxas has announced that the CEPI, has approved the progression of a $7.2 million program to develop heat-stable, ...

Vaxxas, a clinical-stage biotechnology company commercializing a novel high-density microarray patch (HD-MAP) vaccination platform, today announced that CEPI, the Coalition for Epidemic Preparedness ...

To compare EI with needle injection through these conventional routes, we used a formalin-inactivated Aichi/68 influenza virus to immunize BALB/c mice (n = 8 per group). For EI, the vaccine was ...

About HD-MAP needle-free vaccines The Vaxxas HD-MAP is comprised of thousands of microscopic projections molded into a small patch. Each microprojection is coated with a small dose of vaccine in a ...